89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022

Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company, has announced that additional data on pegozafermin for treating non-alcoholic steatohepatitis (NASH) will be presented at the EASL International Liver Congress™ 2022 in London from June 22-26, 2022. Key presentations include:

• Abstract 3535: Improved liver histology and metabolic profile.
• Abstract 3654: Significant metabolic benefits alongside liver improvements.
• Abstract 1520: Pharmacokinetics of BIO89-100 in NASH patients.

Presentations are on June 25, 2022.

SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic steatohepatitis (NASH) will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, to be held in London, UK on June 22-26, 2022.

Presentation details are as follows:

Abstract Title: Pegozafermin Led to Improved Liver Histology, Liver-related Non-invasive Tests and Metabolic Profile, With Favorable Safety and Tolerability, in an Open-label Cohort of a Phase 1b/2a Study in Subjects With Non-alcoholic Steatohepatitis
Abstract Number: 3535
Format: Poster presentation (#SAT-139)
Presenting Author: Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego
Presentation Date and Time: Saturday, June 25^th 9:00 – 18:30 BST

Abstract Title: Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH)
Abstract Number: 3654
Format: Poster presentation (#SAT-143)
Presenting Author: Naim Alkhouri, MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH)
Presentation Date and Time: Saturday, June 25^th 9:00 – 18:30 BST

Abstract Title: Pharmacokinetics (PK) and Pharmacodynamics (PD) of BIO89-100, a Novel GlycoPEGylated FGF21, in Nonalcoholic Steatohepatitis (NASH) Patients with Compensated Cirrhosis
Abstract Number: 1520
Format: Poster presentation (#SAT-131)
Presenting Author: Naim Alkhouri, MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH)
Presentation Date and Time: Saturday, June 25^th 9:00 – 18:30 BST

About 89bio 
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Ryan Martins 
Chief Financial Officer 
investors@89bio.com 

FAQ

What data about ETNB was presented at the EASL International Liver Congress 2022?

89bio presented additional data on pegozafermin for NASH at the EASL International Liver Congress 2022.

When will 89bio's presentations on pegozafermin take place?

The presentations are scheduled for June 25, 2022.

What are the key abstracts presented by 89bio at the EASL congress?

Key abstracts include improved liver histology, significant metabolic benefits, and pharmacokinetics of BIO89-100 in NASH patients.

Who are the presenting authors for 89bio's studies at the EASL congress?

Presenting authors include Rohit Loomba, MD, and Naim Alkhouri, MD.

What is the focus of 89bio's clinical research?

89bio focuses on developing therapies for liver and cardio-metabolic diseases, particularly NASH.